Cagrilintide — Spray

Scientific identity

Cagrilintide (CAS 1415456-99-3; PubChem CID 171397054; DrugBank DB18887), also designated AM833 and NN9838, is a synthetic lipidated 37-residue amylin analogue. Molecular formula C₁₉₄H₃₁₂N₅₄O₅₉S₂; molecular weight approximately 4,409 Da. Key structural features include the 37-residue backbone, an intramolecular disulfide bridge between Cys3 and Cys8, and an N-terminal C20 fatty diacid modification via a γ-glutamyl linker enabling albumin binding.

Compound class

Synthetic lipidated amylin analogue; long-acting acylated amylin research compound; non-selective AMY/CTR agonist. Classified as a Research Use Only material and is not a drug, dietary supplement, food, or cosmetic.

Structural design rationale

Native amylin forms amyloid fibrils — making it difficult to handle as a research tool — and has a half-life of minutes. Pramlintide, the first-generation clinical analogue, addressed fibril formation by substituting three prolines but retained a short half-life (~50 minutes). Cagrilintide builds on this scaffold with additional modifications, most critically N-terminal acylation with a C20 fatty diacid via a γ-glutamyl spacer enabling reversible albumin binding, which reduces renal clearance and extends the functional half-life to approximately 180 hours in human pharmacokinetic studies. This engineering enables once-weekly experimental protocols in preclinical and clinical research contexts.

Primary molecular targets

Non-selective agonist of amylin receptor subtypes AMY1R (CTR + RAMP1), AMY2R (CTR + RAMP2), and AMY3R (CTR + RAMP3), and of the calcitonin receptor (CTR) itself. Amylin receptors are heterodimeric GPCRs formed by the association of the calcitonin receptor with receptor activity-modifying proteins (RAMPs).

CAS note

CAS 1415456-99-3 is the primary chemical registry number for cagrilintide as catalogued in multiple authoritative databases. A second CAS (2375393-84-7) appears on some commercial listings and may correspond to a specific salt or formulation form; researchers should confirm which identifier applies to their specific material from the batch Certificate of Analysis.

Product content

10mg per bottle; 45 sprays per bottle. Per-spray quantity is documented on the product label and batch Certificate of Analysis.

Physical form: Liquid research spray.

Purity: Research-grade. As a lipidated compound, cagrilintide may be sensitive to temperature, light, and oxidative conditions; researchers should follow the COA's lot-specific storage guidance.

Analytical documentation

A batch-specific Certificate of Analysis is available on the Longevia Research website, covering compound identity, purity, and lot traceability. Mass spectrometric confirmation at approximately 4,409 Da simultaneously confirms the 37-residue backbone, the intramolecular disulfide bridge, and the C20 fatty diacid modification — distinguishing cagrilintide from unacylated precursor material, reduced open-chain disulfide forms, and sequence-related impurities. The lipid conjugate also confers distinct chromatographic retention useful for both identity confirmation and purity determination.

Research-use classification

Research Use Only. Not approved for human or veterinary use. Not intended for administration to humans or animals.

Amylin biology and research context

Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide hormone co-secreted with insulin by pancreatic beta cells in response to nutrient intake. In contrast to insulin, which acts primarily on peripheral tissues, amylin exerts a significant proportion of its effects through the central nervous system — primarily through brainstem and hypothalamic circuits — and on gastrointestinal physiology. Established biological actions of endogenous amylin in experimental models include slowing of gastric emptying, suppression of post-prandial glucagon secretion, and modulation of food intake through central satiety pathways. Amylin receptors are also expressed in bone and kidney, contributing to the hormone's complex multi-tissue biology. The challenge of studying amylin pharmacology directly is the parent molecule's tendency to form amyloid fibrils, making unmodified amylin difficult to handle as a research tool; cagrilintide addresses this through structural engineering while providing a substantially extended pharmacokinetic window relative to all previous amylin-class research compounds.

Receptor pharmacology and preclinical research

Amylin receptors are heterodimeric GPCRs formed by the calcitonin receptor (a Class B GPCR) in association with one of three receptor activity-modifying proteins, producing AMY1R, AMY2R, and AMY3R subtypes. This heterodimeric architecture means amylin pharmacology is mechanistically intertwined with calcitonin receptor pharmacology — compounds binding the amylin receptor complex necessarily engage the CTR subunit. Fletcher and colleagues (Journal of Pharmacology and Experimental Therapeutics, 2021; PMID 33619192) characterized cagrilintide as AM833 across this receptor family in cellular receptor pharmacology assays, defining its non-selective agonist activity and selectivity profile relative to other amylin-class compounds. The foundational preclinical pharmacology was published by Kruse and colleagues (Journal of Medicinal Chemistry, 2021; PMID 34288673) at Novo Nordisk; in rodent studies, cagrilintide at doses of 0.1–30 nmol/kg subcutaneously produced dose-dependent reductions in food intake sustained over several days, with pharmacokinetic characterization in rats and rabbits reporting half-lives of 20±2 hours (intravenous) and 27±3 hours (subcutaneous) — shorter than the approximately 180 hours observed in human pharmacokinetic modeling, consistent with known interspecies allometric differences in albumin-binding half-life extension. These are pharmacological observations in defined experimental model systems and do not establish equivalent effects in humans.

Human clinical research programme

Cagrilintide has accumulated a substantial published human clinical research record. A 26-week, double-blind, placebo-controlled Phase 2 monotherapy dose-finding trial examined once-weekly subcutaneous cagrilintide at five doses in 706 adults with obesity or overweight plus comorbidities, with the highest dose arm (4.5 mg) reporting approximately 10.8% mean weight loss versus approximately 3.0% on placebo; dose-dependent gastrointestinal adverse events were the most commonly reported findings across dose arms. The Phase 3 REDEFINE programme examined CagriSema — a co-formulation of cagrilintide 2.4 mg and semaglutide 2.4 mg — rather than cagrilintide monotherapy: REDEFINE 1 (adults with obesity without diabetes, 68 weeks) reported approximately 22.7% mean weight reduction with CagriSema versus placebo by the trial-product estimand; REDEFINE 2 (adults with obesity and type 2 diabetes) reported approximately 15.7% weight reduction at 68 weeks. REDEFINE trial results reflect the fixed combination and cannot be attributed to cagrilintide alone. The combination research rationale reflects the pharmacological logic that amylin receptor activation and GLP-1 receptor activation engage distinct but complementary mechanisms — amylin acting primarily through brainstem area-postrema circuits and calcitonin receptor-rich hypothalamic regions; GLP-1 acting through hypothalamic G

For a complex lipidated peptide such as cagrilintide, analytical quality documentation addresses multiple structural features simultaneously: the 37-residue backbone sequence, the intramolecular Cys3–Cys8 disulfide bridge, and the C20 fatty diacid N-terminal modification via the γ-glutamyl linker. Each of these elements must be confirmed for the material to be correctly characterised — mass spectrometric confirmation at the intact peptide level provides a molecular weight consistent with C₁₉₄H₃₁₂N₅₄O₅₉S₂ at approximately 4,409 Da, confirming all three structural elements simultaneously.

Identity confirmation: Each production lot of Longevia's cagrilintide spray is characterised by mass spectrometric analysis, verifying the observed molecular ion against the expected mass for the fully acylated, disulfide-bonded peptide. This distinguishes cagrilintide from unacylated precursor material, reduced (open-chain) disulfide forms, or sequence-related impurities.

Purity assessment: Chromatographic purity analysis quantifies the target compound against all other UV-absorbing species in the chromatogram. For a lipidated peptide, the fatty acid conjugate confers distinct chromatographic retention that is analytically useful for both identity confirmation and purity determination.

Batch traceability and Certificate of Analysis: Every production lot of cagrilintide 10mg spray is traceable to a specific batch. A batch-specific Certificate of Analysis is accessible on the Longevia Research website, covering compound identity, purity, and lot information. Researchers are encouraged to review current batch documentation before use.

Storage: Specific storage conditions and stability information for this lot are confirmed on the batch Certificate of Analysis and product labelling. Lipidated peptide research compounds can be sensitive to temperature, light, and oxidative conditions; researchers should follow the COA's lot-specific guidance.

Longevia Research supplies Cagrilintide 10mg Spray for laboratory and in-vitro research use only. The product is intended for qualified researchers and trained laboratory personnel working in appropriate controlled research environments.

Cagrilintide is an investigational synthetic research compound supplied strictly as a laboratory research tool. It is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. No regulatory authority has approved cagrilintide for any human or veterinary therapeutic use. A New Drug Application for CagriSema (a co-formulation of cagrilintide with semaglutide) was filed by Novo Nordisk in December 2025; no approval has been issued as of the date of this publication. The Longevia research material is not the compound used in Novo Nordisk's clinical programme and carries no pharmaceutical status.

The clinical trial findings referenced on this page describe results from Novo Nordisk-sponsored research under specific clinical protocols. They do not establish that the Longevia research material is safe or effective for any human application. No dosing instructions, spray-frequency guidance, administration protocols, or cycle recommendations are provided. The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations.